ERBB2 and cancer: In the overall TCGA Pan-Cancer cohort, although the HER2 protein expression measured by RPPA was not altered, significantly higher MSI incidence (14% vs. 3.2%), TMB, and TNB were observed in samples with HER2 mutations than in those with HER2 wild-type (p<0.05; Figure 2A).